Investor Relations
Reporting 3rd Quarter 2020
On November 3rd, 2020, Evonik has published its quarterly report Q3 2020. You can access further information here. ... MORE
Company
Annual Shareholders' Meeting 2020
On August 31, 2020, the annual shareholders' meeting has been held as a virtual shareholders' meeting. You can access further information here. ... MORE
Investor Relations
Acquisition of Porocel
Evonik is acquiring the Porocel Group for US$210 million to accelerate the growth of its catalysts business. ... MORE
Further Information
Company
Events & Presentations
Here you will find dates, information and presentations on our events. ... MORE
Company
Analysts' estimates
Evonik Industries AG is covered by German and international financial analysts, who provide their own research analyses and earnings estimates in respect of the company. ... MORE
Company
News & Reports
Here you can find "Investor Relations News" with the latest news from our company, plus our most recent interim reports, annual reports and corporate responsibility reports. ... MORE
Reporting 2020/2021
-
November 3, 2020Quarterly Report Q3 2020
-
March 4, 2021Quarterly Report Q4 and Full Year 2020
-
May 6, 2021Quarterly Report Q1 2021
-
June 2, 2021Annual Shareholders' Meeting
-
August 5, 2021Quarterly Report Q2 2021
-
November 4, 2021Quarterly Report Q3 2021
Investor Relations
Dec 07, 2020
Fight against COVID-19: Evonik supplies key technology for gene-based drugs
The COVID-19 pandemic has prompted a breakthrough in gene-based vaccines using a technology in which Evonik is a global leader ... MORE
Investor Relations
Nov 12, 2020
Evonik to complete the consolidation of its European production network for household care products this month
Evonik will this month complete the consolidation of its European manufacturing activities for fabric softener ingredients to its world-class production sites ... MORE
Investor Relations
Nov 03, 2020
Evonik successfully completes acquisition of Porocel
On November 3, 2020, Evonik completed the acquisition of the Porocel Group, Houston (USA), for US$ 210 million, as planned. ... MORE
Investor Relations
Nov 03, 2020
Evonik is getting through the crisis well
Despite the persistently challenging macroeconomic environment, Evonik continues to manage well in the crisis. ... MORE
Investor Relations
Oct 15, 2020
Evonik delivers Q3 adjusted EBITDA of €519 million above market expectations
Despite the challenging macroeconomic environment, Evonik continues to withstand the crisis well. ... MORE
Investor Relations
Oct 13, 2020
Evonik to concentrate MetAMINO® production at its three, world-scale, best-in-class hubs
Evonik is to cluster its MetAMINO® (DL-methionine) production at three international hubs (Americas, Europe, and Asia) to maximize economies of scale and utilize robust processes. ... MORE
Further Information
Company
Financial data
Evonik is active in over 100 countries around the world. In fiscal 2018 more than 36,000 employees generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.6 billion. ... MORE
Company
Bonds & Rating
Evonik maintains a centralized approach to financing. Liabilities for credit and loans are fully guaranteed by Evonik Industries AG. ... MORE
Company
Key Figures Share
Here you find information about Evonik shares. ... MORE
Company
Contact & Service
You can find the contacts in the Investor Relations Department here. ... MORE
Company
Disclaimer
Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained. ... MORE
Company
Corporate Governance
As a globally active company, we have to comply with a wide range of statutory regulations and cultural standards. ... MORE
Investor Relations
Sustainable Investment (SRI)
We accept responsibility for our businesses, our employees, the environment and the society. ... MORE